Abstract:
composições farmacêuticas compreendendo derivados de poh. a presente invenção proporciona um derivado de monoterpeno ou sesquiterpeno, tal como um derivado de álcool perílico. por exemplo, o derivado de álcool perílico pode ser um carbamento de álcool perílico. o derivado de álcool perílico pode ser álcool perílilo conjugado com um agente terapêutico tal como um agente quimioterapêutico. a presente invenção também proporciona um método de tratar uma doença tal como câncer, compreendendo a etapa de enviar a um paciente uma quantidade terapeuticamente eficaz de um derivado de monoterpeno (ou sesquiterpeno). a via de administração pode variar, e pode incluir inalação, intranasal, oral, transdérmica, intravenosa, subcutânea ou injeção intramuscular.
Abstract:
The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w) The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w) The purified monoterpene can be used to treat a disease such as cancer The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
Abstract:
The present invention, provides for a deuterium-enriched monoterpene or sesquiterpene such as perillyl alcohol, or a deuterium-enriched isomer or analog of monoterpenes or sesquiterpenes, such as isoperillyl alcohol. The present invention also provides for a deuterium-enriched derivative of a monoterpene or sesquiterpene, such as a perillyl alcohol carbamate, or a deuterium-enriched derivative of an isomer or analog of a monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The deuterium-enriched derivative may be perillyl alcohol or isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a deuterium-enriched compound.
Abstract:
The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w) The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w) The purified monoterpene can be used to treat a disease such as cancer The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
Abstract:
The present invention, provides for a deuterium-enriched monoterpene or sesquiterpene such as perillyl alcohol, or a deuterium-enriched isomer or analog of monoterpenes or sesquiterpenes, such as isoperillyl alcohol. The present invention also provides for a deuterium-enriched derivative of a monoterpene or sesquiterpene, such as a perillyl alcohol carbamate, or a deuterium-enriched derivative of an isomer or analog of a monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The deuterium-enriched derivative may be perillyl alcohol or isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a deuterium-enriched compound.